Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up.
This placebo-controlled , double-blind , 1-year pilot study aim ed at investigating possible clinical advantages of combining initial light therapy with the selective serotonin reuptake inhibitor ( SSRI ) citalopram as well as the effects of continuous long-term administration of this drug in patients with seasonal affective disorder ( SAD ) . Eight physically healthy women who met the DSM-III-R criteria for SAD were included in the study . Four women were r and omized to the citalopram group receiving 40 mg citalopram daily from the first of 10 light treatment days and throughout the 1-year study . The remaining four women were allocated to the placebo group using the same double-blind repeated measures design . The clinical outcome was measured by using three versions of the Comprehensive Psychopathological Rating Scale ( CPRS ) and Visual Analog Scales ( VAS ) , respectively . Taking the initial rating scores into account in covariance analyses , no statistically significant group difference was found during the light treatment period . However , during the follow-up period the full version of the CPRS and the self-rating version of CPRS and the VAS-scales for global condition and depressed mood were statistically significantly lower in the citalopram group compared with the placebo group . Thus , in this small but carefully observed sample of SAD- patients combining initial light therapy and long-term citalopram treatment was clinical ly more effective over time than the placebo combination . Our findings support the notion that light therapy with concomitant and continued SSRI ( citalopram ) treatment is a useful strategy to achieve beneficial long-term effects in patients with the SAD syndrome
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .